NEURO-XI LTD
Neuro-Xi Ltd is a clinical-stage biotechnology company focused on developing precision brain therapies using focused ultrasound technology.
Profile
Develops non-invasive ultrasound systems that enhance drug delivery to the brain for treating cancers and neurodegenerative diseases.
Neuro-Xi Ltd is a clinical-stage biotechnology company focused on developing precision brain therapies using focused ultrasound technology. The company emerged from a strategic spin-out of Insightec's neuro-focused division in December 2025, backed by Nexus NeuroTech Ventures. Neuro-Xi's core platform builds on Insightec's FDA-approved focused ultrasound system, which has been used to treat over 25,000 patients for conditions like essential tremor and Parkinson's disease.
The company's lead programs target glioblastoma and diffuse midline gliomas, with initial clinical data showing improved chemotherapy delivery and survival rates when combined with blood-brain barrier opening. Neuro-Xi operates as a separate entity from Insightec but maintains close collaboration on device integration and translational research. The company is led by CEO Arjun Desai, a former Johnson & Johnson Innovation executive who previously headed strategic initiatives at Insightec.
Neuro-Xi's approach combines therapeutic ultrasound with biologic, genetic, and cellular therapies—a model that attracted $120 million in Series A funding from Nexus NeuroTech and other life science investors in Q1 2026. Recent Lancet Oncology-published data demonstrated a 32% survival improvement in glioblastoma patients receiving ultrasound-enhanced chemotherapy, positioning Neuro-Xi at the forefront of non-invasive brain treatment platforms.
Who buys this
- Academic medical centers with neuro-oncology programs
- Pharmaceutical companies developing CNS therapies
- Specialty hospitals treating movement disorders
- Neurology clinics in developed healthcare markets
Strengths and what to watch
Strengths
- Proprietary focused ultrasound platform with FDA approvals for related neurological indications
- Clinical validation from published glioblastoma survival data in The Lancet Oncology
- Strategic partnership with Insightec for device manufacturing and IP access
Watch for
- Dependence on continued collaboration with Insightec for core technology
- High capital intensity of clinical trials for new therapeutic combinations
- Competitive pressure from emerging blood-brain barrier penetration technologies
Recent moves
Key Information
- Founded
- 2025
Frequently Asked Questions
What does Neuro-Xi Ltd do?
Neuro-Xi develops non-invasive ultrasound systems to enhance drug delivery for brain cancers and neurodegenerative diseases. Their FDA-cleared technology temporarily opens the blood-brain barrier, improving chemotherapy effectiveness. The company spun out from Insightec in 2025 and focuses on glioblastoma and other neurological conditions.
How does focused ultrasound help treat brain tumors?
Neuro-Xi's ultrasound platform temporarily opens the blood-brain barrier, allowing better chemotherapy drug penetration. Published data in Lancet Oncology showed a 32% survival improvement in glioblastoma patients. The technology builds on Insightec's existing FDA-approved systems used for neurological disorders.
What are Neuro-Xi's most promising treatments?
Their lead programs target glioblastoma and diffuse midline gliomas, with clinical data showing improved chemotherapy delivery. The system combines ultrasound with biologic, genetic, and cellular therapies. Initial results demonstrate survival benefits, positioning it as a potential breakthrough for hard-to-treat brain cancers.
Who funds Neuro-Xi's research?
The company raised $120 million in Series A funding in Q1 2026, led by Nexus NeuroTech Ventures. This followed their 2025 spin-out from Insightec with initial backing from the same investors. Funding supports clinical trials for ultrasound-enhanced brain therapies.
Where is Neuro-Xi's technology being used?
Their systems target academic medical centers with neuro-oncology programs, specialty hospitals, and neurology clinics. Pharmaceutical companies developing CNS therapies also partner with Neuro-Xi. Initial adoption focuses on developed healthcare markets with advanced neurological treatment capabilities.
What challenges does Neuro-Xi face?
Key challenges include dependence on Insightec for core technology, high clinical trial costs for therapeutic combinations, and competition from emerging blood-brain barrier technologies. However, their published clinical data and FDA-cleared platform provide competitive advantages in neurotherapy development.
Sources
- www.prnewswire.com — Spin-out announcement and initial funding details
- www.thelancet.com — Glioblastoma clinical trial results
- www.linkedin.com — CEO background
- www.nexusneurotech.com — Investor profile